Unique ID issued by UMIN | UMIN000004914 |
---|---|
Receipt number | R000005563 |
Scientific Title | Validity of Sputum Induction Method for the Diagnosis of Lung Cancer |
Date of disclosure of the study information | 2011/01/21 |
Last modified on | 2015/02/03 12:51:01 |
Validity of Sputum Induction Method for the Diagnosis of Lung Cancer
Sputum Induction in Patients with Lung Cancer
Validity of Sputum Induction Method for the Diagnosis of Lung Cancer
Sputum Induction in Patients with Lung Cancer
Japan |
Patients with suspected lung cancer
Pneumology | Hematology and clinical oncology | Adult |
Malignancy
YES
We aimed to evaluate the efficacy of induced sputum obtained by inhalation of hypertonic saline for 15 minutes, for the diagnosis of lung cancer.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
Sputum expectoration rate
1. Cytological examination of sputum induced by 10% hypertonic saline
2. Analysis of adverse events arising from the inhalation of 10% hypertonic saline
3. Testing of the lung carcinoma cells for EGFR gene mutation in sputum cytology-positive cases and comparison of the test results between spontaneous and induced sputum specimens
4. Questionnaire survey of the patients.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
Maneuver |
Spontaneous sputum cytology specimens were collected from each subject for 3 days after registration. On each day during the subsequent 3-day period, each subject was asked to inhale nebulized 10% hypertonic saline (mixed with 0.5 mL salbutamol), in an attempt to induce sputum. Immediately before each session of sputum induction, the oral cavity was cleared of food residues and mucus. During the 15-minute saline inhalation, sputum was collected in a sterile dish. Three slides were prepared from each sputum sample, fixed in 95% ethanol, and stained with Papanicolaou method. After completion of the protocol, all patients fulfilled a questionnaire containing 4 questions on the induction procedures.
18 | years-old | <= |
Not applicable |
Male and Female
Patients with suspected lung cancer based on the detection of an abnormal opacity on the chest X-ray. Written informed consent
(1) patients with uncontrolled asthma, (2) patients with severe hepatopathy, nephropathy, cardiac disease or hematological disease, or other serious complications, (3) pregnant or possibly pregnant women, and (4) other patients judged by the physician as being unsuitable candidates for the study.
100
1st name | |
Middle name | |
Last name | Yuka Fujita |
National Hospital Organization Asahikawa Medical Center
Clinical Reseach
7 Hanasaki-cho Asahikawa Hokkaido 070-8644 Japan
0166-51-3161
yuka-1@hosp.go.jp
1st name | |
Middle name | |
Last name | Yuka Fujita |
National Hospital Organization Asahikawa Medical Center
Respiratory Medicine
7 Hanasaki-cho Asahikawa Hokkaido 070-8644 Japan
0166-51-3161
yuka@asahikawamc.hosp.go.jp
National Hospital Organization Asahikawa Medical Center
None
Self funding
NO
国立病院機構旭川医療センター
2011 | Year | 01 | Month | 21 | Day |
Unpublished
Enrolling by invitation
2009 | Year | 03 | Month | 25 | Day |
2010 | Year | 12 | Month | 01 | Day |
2013 | Year | 11 | Month | 01 | Day |
2011 | Year | 01 | Month | 20 | Day |
2015 | Year | 02 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005563
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |